25 August 2025
: Case report 
Rapid Progression of Primary Hepatic Neuroendocrine Carcinoma: A Case Report Demonstrating Drastic Oncological Behavior
Challenging differential diagnosis, Diagnostic / therapeutic accidents, Rare disease, Adverse events of drug therapy
Rina Kobayashi BF 1, Tomohide Hori
ABCDEF 1*, Makoto Yamawaki CDF 2, Shigeki Nakayama DF 1, Satoru Umegae DF 1, Takao Iwanaga DF 1, Ryutaro Nishikawa D 1, Takahiro Shimoyama DF 1, Sakurako Suzuki F 1, Shinichiro Atsumi CDF 3, Hiroshi Hasegawa F 2, Shigehito Nakashima DF 2, Kunihiro Higuchi F 2, Kentaro Onishi F 2, Ryotaro Sakaguchi F 2, Shoichi Morita F 2, Haruka Miyao F 2, Saki Aota F 2, Hikaru Ohtani F 1, Takayuki Yamamoto ADF 1
DOI: 10.12659/AJCR.948500
Am J Case Rep 2025; 26:e948500
Figure 9 Clinical course, serum level of PIVKA-II, and oncological progressionCT – computed tomography; MRI – magnetic resonance imaging; PET/CT – positron emission-based tomography/computed tomography; PIVKA-II – protein induced by vitamin K absence or antagonist-II; US – ultrasound.